Cactus Life Sciences
24.4.2024 15:48:41 CEST | ACCESS Newswire | Press release
Cactus Life Sciences has begun their exciting buy-and-build strategy adding key services to their portfolio
PRINCETON, NJ / ACCESSWIRE / April 24, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that they have acquired nspm and eluSCIdate, two dynamic medical communications and publications companies headquartered in Meggen, Switzerland with an office in the UK.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.logo lockup
Cactus Life Sciences, headquartered in Princeton, New Jersey, was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. Founded 27 years ago, nspm brings extensive expertise in medical communications, publications, and event management, with a focus on rare diseases. Its sister company eluSCIdate was founded in 2020 and focuses on medical and scientific publications, combining extensive experience in medical writing with creative flair to deliver high-quality publications.
This collaboration signifies a major step forward in enhancing services for our biopharma clients, ensuring a comprehensive and fully integrated global approach to medical communications. And provides a significant employee footprint in US, UK, Switzerland, and Japan.
"As Cactus Life Sciences embarks on its forthcoming buy-and-build strategy, we're excited to unveil our first acquisition that shares so many of the same values as CACTUS, stated Oliver Dennis, the new Chairman of Cactus Life Sciences. "As we move forward, we seek partnerships that prioritize our people and clients alongside our strategic growth."
Rare diseases individually affect a small number of people, but collectively affect over 300 million worldwide, presenting significant challenges for patients and medical professionals. nspm's rare disease expertise addresses unmet needs for patients and society. Sabine Stotz, PhD, Managing Director, nspm, noted "This strategic alliance is a testament to the shared vision of excellence between Cactus Life Sciences, nspm and eluSCIdate. Together, our goal is to enrich the global landscape of scientific communications creating an even greater impact on healthcare professionals and the patients they treat".
Elvira Dsouza, President, Cactus Life Sciences remarked, "Cactus Life Sciences stands out for its unwavering commitment to excellence, innovation, and future readiness. With a focus on integrating cutting-edge technology, notably AI, we aim to elevate scientific content creation to contribute to a more accessible, informed, and transformative healthcare landscape".
About Cactus Life Sciences (cactuslifesciences.com): Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.
About nspm (www.nspm.com): nspm is a successful and dynamic medical communications company founded in 1997 with offices in Switzerland and the UK. nspm provides a complete range of medical writing, project management, and strategic medical communications solutions for the pharmaceutical and biotech industry across a range of therapeutic areas, with a focus on rare diseases. Our employees are committed to crafting high-quality, cost-effective solutions that exceed clients' expectations through scientific excellence, professionalism, and creativity.
About eluSCIdate (www.eluscidate.com): eluSCIdate is a medical writing agency founded in 2020 that specializes in scientific publications, providing support for the entire publication process. We use a wealth of experience in medical writing to deliver high-quality manuscripts, posters, and slides to our clients. At eluSCIdate, we are passionate about science and committed to providing clarity in scientific messaging. Through effective communication, we work with our clients to ensure their science stands out from the crowd.
Contact Information:
Laura Perry
VP of Strategy and Marketing
inquiries@cactuslifesciences.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Announces Early Launch of Prime Sale, Featuring Limited Omni Bundle Flash Deals Starting Today18.6.2026 04:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 17, 2026 / LiberNovo today opened early access to its 2026 Prime Sale, with up to 49% off and a limited run of flash-deal bundles built around the original LiberNovo Omni. Early access is live now, and the full sale runs June 23 through July 11. LiberNovo makes dynamic ergonomic chairs, the first designed to respond to your body as it moves. Instead of locking you into one fixed posture, the dynamic support system keeps the neck support, backrest, armrests, and seat moving together as you shift, lean, and recline. Prime Sale - Omni Series Clearance Deals The original LiberNovo Omni is available at Prime Sale clearance pricing while stocks last, with prices starting as low as €939 (49% off in the EU) and £869 (46% off in the UK), representing significant savings for consumers. The original LiberNovo Omni - the first dynamic ergonomic chair - features an eight-panel Bionic FlexFit Backrest and automatic armrests that move with you through every shif
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders17.6.2026 23:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 17, 2026 / Polaris Renewable Energy Inc. (the "Corporation" or "Polaris") today announced that its annual meeting of shareholders (the "Meeting"), originally scheduled to be held on June 18, 2026 at 9:00 a.m. (Toronto time), has been postponed. The Meeting will now be held as follows: Date: June 26, 2026 Time: 9:00 a.m. (Toronto time) Format: Virtual-only meeting Webcast: https://virtual-meetings.tsxtrust.com/1923 Password: "polaris2026" The Meeting will be conducted in the same virtual format as previously announced, and shareholders will continue to be able to attend, participate and vote online through the TSX Trust virtual meeting platform. Purpose of Postponement The postponement is being done as the required quorum of 50.1% of shareholders voting has not been achieved at this point in time. We encourage shareholders that have not yet voted their shares to do so prior to 9 am on June 25th. Meeting Materials and Business The business of the Meet
Innodata Appoints Jayant Chauhan as Chief Financial Officer17.6.2026 22:30:00 CEST | Press release
Brings More Than Two Decades of Experience in Finance and Scaling High-Growth Technology Companies, Effective July 6, 2026 Interim CFO Marissa Espineli to Transition to Chief Accounting Officer NEW YORK, NY / ACCESS Newswire / June 17, 2026 / INNODATA INC. (Nasdaq:INOD) ("Innodata" or the "Company") today announced that it has appointed Jayant Chauhan as Executive Vice President and Chief Financial Officer (CFO), effective July 6, 2026. At that time, Marissa Espineli, who is serving as the Company's Interim Chief Financial Officer, will transition to the new role of Chief Accounting Officer, reporting to Mr. Chauhan. Mr. Chauhan brings to Innodata more than two decades of experience building and leading finance functions for fast-growing global technology companies. He most recently served as Senior Vice President, M&A at Mphasis, a Blackstone-owned, publicly traded global IT services company, and previously as Senior Vice President, Global Strategic Finance, and CFO of the operated ho
Qualitest Becomes QualityAI: The Trusted Assurance and Engineering Partner Across Every Stage of Enterprise AI17.6.2026 18:45:00 CEST | Press release
As businesses double down on AI deployment, QualityAI helps enterprise leaders move beyond AI claims and go live with confidence. LONDON, UK / ACCESS Newswire / June 17, 2026 / Qualitest, the leading provider of AI-first quality engineering and assurance, today announces its rebrand to QualityAI. The new brand reflects the company's evolution from software testing specialist to AI-first quality engineering partner, helping enterprises design quality into complex systems from the outset. Across every industry, companies are racing to adopt AI, and the pressure to demonstrate progress is rising. According to Deloitte's 2026 "State of AI in the Enterprise" report, the proportion of organizations expecting at least 40% of AI experiments to reach production is expected to more than double within six months. As AI moves from ambition to implementation, leaders need to prove that transformation is real, reliable, and effective. In a market crowded with AI claims, assurance is becoming the dif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom